SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD Law
1. Robbins Geller is investigating SLNO for potential securities law violations.
2. Soleno's CEO acknowledged disruptions in VYKAT XR's launch trajectory.
3. VYKAT XR's discontinuation rate from adverse effects is reported at 8%.
4. After negative reports, SLNO shares fell more than 26%.
5. Investors affected by these issues may seek legal recourse.
The investigation may lead to stock manipulation concerns, similar to past fraud cases that impacted share prices significantly.
How important is it?
Given the investigation's implications for SLNO's compliance and investor trust, the likelihood of a price impact is high.
Why Long Term?
The potential legal ramifications and investor sentiment may affect SLNO for an extended period, much like historical cases that took years to resolve.
SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ:SLNO) focused on whether Soleno and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in the Soleno investigation or if you are a Soleno investor who suffered a loss and would like to learn more, you can provide your information here:
THE COMPANY: On March 26, 2025, Soleno announced that the U.S. Food and Drug Administration had approved VYKAT XR (diazoxide choline) extended-release tablets for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.
THE REVELATION: On November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of VYKAT XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno's CEO, Anish Bhatnagar, further admitted during the call that Soleno "did see a disruption in our [VYKAT XR] launch trajectory in the wake of a short seller report that was released in mid-August, mostly in the form of a lower number of start forms and increase discontinuations for non-serious adverse events." After this news, the price of Soleno shares fell more than 26%.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com
